Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2012 5
2013 4
2014 3
2015 2
2016 2
2017 7
2018 15
2019 11
2020 9
2021 5
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee.
Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Messé SR, Perino AC, Rodriguez F, Sarode R, Siegal DM, Wiggins BS. Tomaselli GF, et al. J Am Coll Cardiol. 2020 Aug 4;76(5):594-622. doi: 10.1016/j.jacc.2020.04.053. Epub 2020 Jul 14. J Am Coll Cardiol. 2020. PMID: 32680646 Free article. No abstract available.
Overview of betrixaban and its role in clinical practice.
Lekura J, Kalus JS. Lekura J, et al. Am J Health Syst Pharm. 2018 Aug 1;75(15):1095-1102. doi: 10.2146/ajhp170785. Epub 2018 Jun 25. Am J Health Syst Pharm. 2018. PMID: 29941506 Review.
In parallel with these results, oral betrixaban therapy was found to be associated with a rate of major bleeding comparable to that associated with subcutaneous enoxaparin therapy; however, betrixaban use was associated with a higher cumulative rate of major and cli …
In parallel with these results, oral betrixaban therapy was found to be associated with a rate of major bleeding comparable to that a …
A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ Jr, Ziebell CM. Milling TJ Jr, et al. Trends Cardiovasc Med. 2020 Feb;30(2):86-90. doi: 10.1016/j.tcm.2019.03.004. Epub 2019 Mar 26. Trends Cardiovasc Med. 2020. PMID: 30952383 Free PMC article. Review.
Investigators have rapidly developed reversal agents for these agents as well, idarucizumab for the Factor IIa inhibitor dabigatran (Pradaxa) and andexanet alfa for the entire class of Factor Xa inhibitors (FXaIs), currently four drugs: rivaroxaban (Xarelto), apixaban (Eliquis), …
Investigators have rapidly developed reversal agents for these agents as well, idarucizumab for the Factor IIa inhibitor dabigatran (Pradaxa …
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM, Brenner MJ. Miller KM, et al. Drugs. 2019 Feb;79(3):291-302. doi: 10.1007/s40265-019-1059-y. Drugs. 2019. PMID: 30719631 Review.
For the primary safety outcome, betrixaban did not significantly increase major bleeding compared with enoxaparin. ...Reduced-dose betrixaban does not appear to provide the same clinical utility as full-dose betrixaban....
For the primary safety outcome, betrixaban did not significantly increase major bleeding compared with enoxaparin. ...Reduced-dose …
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. Douxfils J, et al. Thromb Haemost. 2021 Aug;121(8):1008-1020. doi: 10.1055/a-1450-8178. Epub 2021 May 30. Thromb Haemost. 2021. PMID: 33742436 Review.
Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban …
Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Dru …
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.
Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogné JM, Mullier F. Douxfils J, et al. J Thromb Haemost. 2018 Feb;16(2):209-219. doi: 10.1111/jth.13912. Epub 2017 Dec 28. J Thromb Haemost. 2018. PMID: 29193737 Free article. Review.
Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approved DOACs (apixaban, betrixaban, dabigatran etexilate, edoxaban and rivaroxaban) have different characteristics impacting assay selecti …
Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approve …
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G, Díaz-Ricart M, Arellano-Rodrigo E. Escolar G, et al. Drugs Today (Barc). 2017 Aug;53(8):423-434. doi: 10.1358/dot.2017.53.8.2681448. Drugs Today (Barc). 2017. PMID: 29119147 Review.
Recent studies have successfully evaluated betrixaban 80 mg once daily in the prevention of VTE in acute medically ill patients in a large phase III trial. This review will address preclinical pharmacology and main aspects of the clinical development of betrixaban a …
Recent studies have successfully evaluated betrixaban 80 mg once daily in the prevention of VTE in acute medically ill patients in a …
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Cohen AT, et al. N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27. N Engl J Med. 2016. PMID: 27232649 Free article. Clinical Trial.
METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 104 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 104 days plus or …
METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of …
Emerging anticoagulants.
Kennedy B, Gargoum FS, Kennedy L, Khan F, Curran DR, O'Connor TM. Kennedy B, et al. Curr Med Chem. 2012;19(20):3388-416. doi: 10.2174/092986712801215847. Curr Med Chem. 2012. PMID: 22680641 Review.
While the modern clinician is familiar with the efficacy and pharmacokinetics of these agents, their adverse effects have provided the impetus for the development of newer anticoagulants with improved safety, ease of administration, more predictable pharmacodynamics …
While the modern clinician is familiar with the efficacy and pharmacokinetics of these agents, their adverse effects have prov …
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG, DeRemer CE, Smith SM, Gums JG. Garland SG, et al. Ann Pharmacother. 2018 Jun;52(6):554-561. doi: 10.1177/1060028018754383. Epub 2018 Jan 17. Ann Pharmacother. 2018. PMID: 29338293
DATA SYNTHESIS: Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation. Betrixaban efficacy and safety has been compared with that of enoxaparin for prophylaxis of VTE in acutely ill medical patients. ...
DATA SYNTHESIS: Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation. Betrixaban effic …
63 results